The U.S. Food and Drug Administration approved Nucala (mepolizumab) for adults and children aged 12 years and older with hypereosinophilic syndrome (HES) for six months or longer without another identifiable non-blood related cause of the disease.

The U.S. Food and Drug Administration approved GlaxoSmithKline plc’s Nucala (mepolizumab) for the treatment of adult and pediatric patients aged 12 years and older with Hypereosinophilic Syndrome (HES) for ≥ six months without an identifiable non-hematologic secondary cause.

A late-stage trial failed to show that BeiGene Ltd.’s cancer treatment Brukinsa was superior to Imbruvica, a rival drug from Johnson & Johnson and AbbVie Inc., for treating WM.

ChemoCentryx and VFMCRP announced that the companies’ pivotal Phase III ADVOCATE clinical trial of avacopan for ANCA-associated vasculitis hit the study’s primary endpoints.

Novartis won FDA approval for a long-delayed version of Amgen’s $4 billion seller Neulasta drug, helping the Swiss drugmaker in an uphill battle to sell copies of rivals’ blockbusters in the U.S.

Eli Lilly and Co.’s experimental pancreatic cancer treatment in combination with chemotherapy drugs failed to meet the main goal of overall survival in a late-stage study.

Researchers may have found a solution to treating a bone marrow cancer proven to be resistant to several standard therapies.

GlaxoSmithKline said an experimental multiple myeloma treatment showed a meaningful response in patients that have run out of three previous treatment options.

In people at high risk for type 1 diabetes, 14 days of therapy with the experimental drug teplizumab delayed development of the disease by a year or more.

Pfizer is ending five preclinical programs in the biosimilar area and cutting 150 positions in Lake Forest, Illinois and in Chennai, India.